Reversible hyperkalemia induced by flufenamic acid in an asymptomatic hyporenemic patient with IgA nephropathy is reported. Flufenamic acid, 600 mg daily, was given for four months to a 64-yearold womanwith biopsy proven IgA-nephropathy. This produced hyperkalemia, hypertension and congestive heart failure with slowly progressive renal impairment. Weconclude that a further suppression of the renin angiotensin system causing selective hypoaldosteronism together with the nephrotoxic effects of this drug mayhave been responsible for hyperkalemia in this patient.
Hyporeninemic hypoaldosteronism (HH) is known to occur in association with diabetes, various renal diseases with mild to moderate renal impairment or in rare instances after chronic sodium bicarbonate abuse. In previous articles, indomethacin-induced hyperkalemia was reported,1' * and a possible mechanism of prostaglandin (PG) inhibition was presented. With the advent of several nonsteroidal anti-inflammatory drugs (NSAIDs) with different potencies for cyclooxygenase inhibition, it is conceivable that HH could occur more frequently during the chronic administration of these agents.
In hypovolemic states induced either by diuretics or sodium depletion, or under decreased renal blood flow, which occurs in congestive heart failure or liver cirrhosis, NSAIDs cause renal impairment of various degrees. Hence, we are warned against their usage in these conditions. We propose that NSAIDs should be administered with extreme caution in patients with asymptomatic HH with or without underlying Laboratory data revealed serum sodium to be 135 mEq/L, potassium, 6.4 mEq/L, blood urea nitrogen 51 mg/dl, and serum creatinine, 2.0 mg/dl when she was on furosemide, digoxine and flufenamic acid. The serum potassium levels ranged between 4.6 and, 7.2 mEq/L on these drugs. PRA was 0.2 ng/ml/h and p-aldo was 1.0 ng/dl on a regular diet containing 120 mEq of sodium and 60 mEq of potassium/day. After the patient's physical condition was improved, a clinical investigation was undertaken in order to clarify the cause of hyperkalemia in relation to low PRA and p-aldo. Sodium and potassium intake was kept constant during the study. In Figure 1, response, whereas p-aldo was low at the baseline, which increased to the normal level at 30 and 60 minutes after injection (Fig. 2) . In the remaining patients, hyperkalemia is found with related symptoms.
Although the diagnostic criteria for HH have not yet been defined, hyperkalemia appears essential for the diagnosis.
In our patient, hyporeninemia and hypoaldosteronism without hyperkalemia was present before HSAID therapy was initiated. The reasons for the normal serum potassium concentration despite persistently low plasma aldosterone levels in this patient are not entirely clear. The explanation may be that plasma aldosterone secretion was not sufficiently reduced to elevate à"the serum potassium concentration, or alternatively, that high dietary sodium and/or low potassium intake might have obscured the development of hyperkalemia. The sodiumpotassium balance study under a regular hospital diet, which was done after the patient become normokalemic, however, does not support the latter possibility. 
